Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

Next Previous
Trial Profile

Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia

Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2018

At a glance

  • Drugs Anti Pseudomonas aeruginosa IgG1 monoclonal antibody (Primary)
  • Indications Pneumonia
  • Focus Therapeutic Use
  • Sponsors Aridis Pharmaceuticals

    • Most Recent Events

    • 02 Aug 2017 According to an Aridis Pharmaceuticals media release, first patient has been enrolled.
    • 02 May 2017 Status changed from not yet recruiting to recruiting.
    • 31 Jan 2017 Status changed from planning to not yet recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top